Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Investing.com -- Estrella Immunopharma Inc (NASDAQ:ESLA) stock surged 21.9% Monday after the clinical-stage biopharmaceutical company announced successful results from the second dose cohort in its STARLIGHT-1 clinical trial.
The company reported a 100% complete response rate at Month 1 in all evaluable patients treated with EB103, its CD19-redirected ARTEMIS T-cell therapy for Advanced B-Cell Non-Hodgkin’s Lymphomas. Notably, no treatment-related serious adverse events were reported during this phase of the study.
The second dose cohort included high-risk patients who were not suitable candidates for commercial CD19 products, including one patient with Central Nervous System lymphoma. These patients had failed multiple prior lines of therapy before receiving the experimental treatment.
"Completing the second dose cohort with a 100% CR rate marks a significant milestone in our EB103 clinical program," said Cheng Liu, CEO of Estrella. "We’re especially encouraged by the favorable safety profile observed in this high-risk group, including a CNS-involved patient, which demonstrates the potential of EB103 as a safe and effective treatment for a broader population of cancer patients who have limited options."
Following the completion of this dose cohort, an independent Data and Safety Monitoring Board will review the cumulative study data to evaluate safety and efficacy, and to determine the Recommended Phase II Dose for the expansion phase of the trial.
The STARLIGHT-1 trial is an open-label, dose escalation, multi-center Phase I/II clinical trial designed to assess EB103 autologous T-cell therapy in adult patients with relapsed or refractory B-cell NHL.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.